A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

Full description

Saved in:
Bibliographic Details
Published in:Nat Commun
Main Authors: Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://ncbi.nlm.nih.gov/pubmed/29691399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03537-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items